PPT-Ticagrelor ADDED to aspirin in Acute NON-SEVERE ISCHEMIC Stroke OR TIA OF ATHEROSCLEROTIC

ORIGIN Pierre Amarenco Hans Denison Scott R Evans Anders Himmelmann Stefan James Mikael Knutsson Per Ladenvall Carlos A Molina Yongjun Wang S Claiborne . Clinical . Director of Endovascular Surgical Neuroradiology, . Neurocritical. care and Clinical Neuroscience Research, . Valley . Baptist Medical Center. Assistant professor, Neurology and Radiology . Jeanne Carroll, RN, BA, CCRC. 2. Ivorine Yu, PhD. 1. Fen-Lei Chang, MD, PhD. 1,2,3. 1. Indiana University School of Medicine – Fort Wayne. 2. Parkview Neuroscience and Stanley Wissman Stroke Center. Children. A Brief . Overview . Tammy . Hennika. , M.D.. Childhood stroke activations. What neuroimaging?. What labs?. What is the treatment? . Can we give . tPA. ?. If not a stroke, what could it be? . Ticagrelor. in Diabetic Patients from the PEGASUS-TIMI 54 Trial. Deepak L. Bhatt, MD, MPH, Marc P. Bonaca, MD, MPH, Sameer Bansilal, MD, . MS, . Dominick J. Angiolillo. , . MD, PhD, Marc Cohen, MD, Robert F. Storey, MD, Kyungah Im, PhD, Sabina A. Murphy, MPH, Peter Held, MD, PhD, Eugene Braunwald, MD, Marc S. Sabatine, MD, MPH, Ph. Gabriel Steg . Can We Open Up the Time Window. ？. David Wang, D.O.,FAHA, FAAN. Director, OSF/INI Stroke Network, CSC at OSF SFMC. Director, Stroke Fellowship. Clinical Professor of Neurology. UICOMP. S. tages of impaired cerebral circulation . Alexandra Czap MD. 1. , Jose-Miguel Yamal PhD. 2. , Noopur Singh MPH. 2. , Stephanie Parker RN. 1. , . Suja. . S. Rajan. PhD. 3. , . Ritvij. . Bowry. MD. 1. , James . Grotta. MD. 4. Department of Neurology, 2. Department of Biostatistics and Data Science, 3. Department of Management, Policy and Community Health . Associate Professor of Clinical Pharmacy,. SBMU. CLASSIFICATION OF ANTIPLATELET AGENTS. Cyclooxygenase inhibitors. Aspirin. Platelet . P2Y12 receptor . blockers. clopidogrel, . ticlopidine. , . ticagrelor. : . New . Agents, New Approaches . Andria L. Ford, . MD. Associate . Professor. Department of Neurology. Division of Cerebrovascular . Diseases. Disclosures. Research Support: . NIH . NHLBI . R01HL129241. OBJECTIVE. นักศึกษาแพทย์ทราบแนวทางการประเมินและวินิจฉัยผู้ป่วยโรคหลอดเลือดสมองเบื้องต้นได้. Assist.Lect. . . Shaymaa. . Hasan. Abbas. DESIRED TREATMENT OUTCOMES. The short-term goals of treatment for acute ischemic stroke include reducing secondary brain damage by re-establishing and maintaining adequate perfusion to marginally ischemic areas of the brain and to protect these areas from the effects of ischemia (i.e., . 89 non-cardioembolic stroke detected by rapid platelet function analyzer Jose C NAVARRO MD MSc , Annabelle Y LAO MD , Maricar P YUMUL MD , Maria Leticia C ARAULLO MD , Johnny K LOKIN MD , Aleja (n . = 6,589). SOCRATES. Primary outcome, death, MI or stroke, for ticagrelor vs. aspirin: . 6.7% . vs. 7.5%, HR = 0.89, 95% CI . 0.78-1.01. , . p = 0.07. Death: 1.0% vs. 0.9%, . p = 0.36; All . strokes: 5.9% vs. 6.8%, . Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial. Gregg W Stone MD. Icahn School of Medicine at Mount Sinai. on behalf of Shao-Liang Chen and the ULTIMATE-DAPT Investigators. Assist.lec. . . Shaymaa. . Hasan. Abbas. Ischemic Heart Disease. The major goals for the treatment of IHD are to:. • Prevent acute coronary syndromes and death . • Alleviate acute symptoms of myocardial ischemia.